TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfills all inclusion criteria for the PA0012 \[NCT04009499\] study~* Subject is considered reliable and capable of adhering to the DV0004 protocol (eg, able to understand and complete questionnaires, able to use investigational self-injecting device presentations according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator~* Subject is willing to self-inject~Exclusion Criteria:~-Subjects are not permitted to enroll in DV0004 if any of the PA0012 \[NCT04009499\] study exclusion criteria are met

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab-SS (Type: EXPERIMENTAL): Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
- Bimekizumab-AI (Type: EXPERIMENTAL): Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhibition of Aldosterone in Patients With Chronic Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proteinuria \> 500 mg/24 hours~* Hypertension or anti-hypertensive treatment~Exclusion Criteria:~* Diabetic nephropathy~* GFR\< 20 ml/min~* P-potassium between 3,5 mmol/l and 5,0 mmol/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Eplerenone
- 2 (Type: NO_INTERVENTION): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H pylori-eradication therapy~* ingestion of antibiotics or bismuth within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 10d bismuth quadruple therapy (Type: ACTIVE_COMPARATOR): rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
- 14d hybrid therapy (Type: EXPERIMENTAL): a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
- 14d high-dose dual therapy (Type: EXPERIMENTAL): rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Established diagnosis of Ulcerative Colitis (UC)~* Moderately to severely active left sided UC assessed by central reading~* Current oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) use or a history of oral 5-ASA/SP use~* Current Glucocorticosteroids (GCS) use or history of GCS dependency, refractory, or intolerance~* Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following agents:~  * Immunomodulators~ * Tumor Necrosis Factor alpha (TNF-α) inhibitors and/or anti-integrins~Exclusion Criteria:~* Suspicion of differential diagnosis~* Acute fulminant UC and/or signs of systemic toxicity~* UC limited to the rectum (disease which extend \<15 cm above the anal verge)~* History of malignancy~* History or presence of any clinically significant disorder~* Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors, anti-integrins or similar immunosuppressants and immunomodulators~* Treatment with rectal GCS, 5-ASA/SP or tacrolimus~* Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)~* Serious active infection~* Gastrointestinal infections~* Currently receiving parenteral nutrition or blood transfusions~* Females who are lactating or have a positive serum pregnancy test~* Women of childbearing potential not using reliable contraceptive methods~* Concurrent participation in another clinical study~* Previous exposure to cobitolimod

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobitolimod Dose 2x31 mg (Type: EXPERIMENTAL): Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 2x125 mg (Type: EXPERIMENTAL): Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 2x250 mg (Type: EXPERIMENTAL): Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
- Cobitolimod Dose 4x125 mg (Type: EXPERIMENTAL): Dose 125 mg of cobitolimod, at 4 occasions
- Placebo (Type: PLACEBO_COMPARATOR): Placebo at four occasions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Patients who completed 8-week short-term treatment study for Major Depressive Episode, NCT00635219 / 11984A~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed., Text revision (DSM-IV TR)~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RG7667 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, 18 to 55 years of age, inclusive~* Body mass index 18.0 to 31.0 kg/m2, inclusive~* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and laboratory values, as deemed by the Investigator~Exclusion Criteria:~* History of malignancy, except completely excised basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ~* History of severe bacterial, fungal, or parasitic infections (more than 2 hospitalizations within 1 year or more than 2 courses of iv antibiotics within 1 year)~* Pregnant, lactating, or planned pregnancy within 6 months of Screening~* Positive for hepatitis B, hepatitis C or HIV infection~* Exposure to any investigational biological agent within 90 days prior to the Screening evaluation or received any other investigational treatment 30 days prior to the Screening evaluation (or within 5 half-lives of the investigational agent, whichever is greater)~* History of alcoholism or drug addiction within 1 year of Screening~* Positive urine test for selected drugs of abuse at Screening and Check-in (Day -1); positive breathalyzer test for alcohol at Check-in~* Use of prescription drugs within 14 days prior to Day 1 or during the study, except for hormonal contraceptives or hormone replacement therapy~* Use of over-the-counter (OTC) medication within 7 days prior to Day 1 or during the study. Medications such as acetaminophen and ibuprofen and routinely-taken dietary supplements, including vitamins and herbal supplements are allowed at the discretion of the investigator and Sponsor.~* Donation of plasma within 7 days prior to Day 1. Donation or loss of blood of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to Day 1.~* Lack of peripheral venous access

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- RG7667 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Main Inclusion Criteria:~Experiencing moderate to severe pain after extraction of impacted third molars~Main Exclusion Criteria:~Any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability Any condition that would render the subject unsuitable to receive an NSAID, acetaminophen or codeine

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibuprofen/acetaminophen (lower dose) (Type: EXPERIMENTAL): One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
- Ibuprofen/acetaminophen (higher dose) (Type: EXPERIMENTAL): Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
- Nurofen Plus® (Type: ACTIVE_COMPARATOR): Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
- Panadeine® Extra (Type: ACTIVE_COMPARATOR): Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-64 years (both inclusive) at the time of signing informed consent~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index 18.5-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)~* Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- FIAsp (Type: EXPERIMENTAL): Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
- NovoRapid® (Type: ACTIVE_COMPARATOR): Each subject will be randomised to a treatment sequence consisting of 8 treatment periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Male between 20 and 45 years of age at the time of screening~2. Subjects with body mass index (BMI) between 20 and 27 at the time of screening~3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 30th days of study completion~4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements~Exclusion Criteria:~1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).~2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption within 6 months from screening~3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.~4. History of drug abuse or positive result at urine drug screening test~5. AST, ALT, r-GT, billirubin(total) values over than 1.5 times of ULN

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 (Type: EXPERIMENTAL): active
- Linezolid (Type: EXPERIMENTAL): comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Disclosure Intervention for People in Recovery From Opioid Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* currently receiving outpatient treatment at the recruitment site~* are considering disclosing their recovery status to at least one person in the next month~* have access to a phone that can receive text messages and phone calls~Exclusion Criteria:~* current diagnosis of severe mental illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Disclosure Intervention Arm (Type: EXPERIMENTAL): Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
- Control Arm (Type: ACTIVE_COMPARATOR): Participants will be able to choose from several guided meditations to promote mindfulness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed symptom history of heartburn, acid regurgitation, or epigastric pain of at least 3 months, while treating with gastric acid modulating therapy (antacids, H2 receptor antagonists (H2RAs) and/or PPIs).~* Heartburn symptoms that average 3 times per week or greater including at least 2 episodes of nighttime heartburn symptoms per week over the past 30 days.~* When heartburn medications were used, subject had heartburn symptoms that were responsive to antacids, non prescription H2RAs, or short term non prescription or prescription PPIs at approved doses but complete resolution of heartburn was not achieved.~Exclusion Criteria:~* A history (past or present) of erosive esophagitis verified by endoscopy.~* The need for continuous treatment with H2RAs, PPIs, gastric prokinetic drugs, or antacids for any indication through the study (eg, long term prescription therapy).~* Subjects requiring continuous intervention by a physician for the treatment of GERD (ie, treatment of erosive esophagitis or prevention of relapse of healed esophagitis).

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 20 mg once daily (Type: EXPERIMENTAL): Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
- Esomeprazole 20 mg twice daily (Type: EXPERIMENTAL): Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally in the morning and placebo administered orally in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetes due to KCNJ11 (Kir6.2) mutation~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's Disease Acitretin Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mild to moderate AD (NINCDS-ADRDA criteria)~* Mini-Mental State Examination (MMSE): 27-14 points~* Geriatric Depression Scale ≤ 14~Exclusion Criteria:~* hereditary cognitive impairment~* known history of brain injuries~* Insufficient German language skills~* actual treatment with other potential disease modifying drugs of AD~* multimorbidity or significant organ (esp. liver or renal) dysfunction~* evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)~* contraindication to acitretin such as osteoporosis, hypoalbuminaemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acitretin (Type: ACTIVE_COMPARATOR): oral, 30 mg per day, day 1-28
- Placebo (Type: PLACEBO_COMPARATOR): oral, day 1-28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant has completed Study ECU-MG-301.~2. Participant has given written informed consent.~3. Participant was willing and able to comply with the protocol requirements for the duration of the study.~4. Female participant of childbearing potential must have had a negative pregnancy test (serum human chorionic gonadotropin). All participants were required to practice an effective, reliable, and medically approved contraceptive regimen during the study and for up to 5 months following discontinuation of treatment.~Exclusion Criteria:~1. Participants who withdrew from Study ECU-MG-301 as a result of an adverse event related to study drug.~2. Female participants who were pregnant, breastfeeding, or intended to conceive during the course of the study.~3. Unresolved meningococcal infection~4. Hypersensitivity to murine proteins or to one of the excipients of eculizumab~5. Any medical condition or circumstances that, in the opinion of the investigator, might have interfered with the participant's participation in the study, posed any added risk for the participant, or confounded the assessment of the participants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab/Eculizumab (Type: EXPERIMENTAL): Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams \[mg\]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study.
- Placebo/Eculizumab (Type: EXPERIMENTAL): Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete